Synergy for streptococcal endocarditis

Synergy for streptococcal endocarditis refers to the adjunctive therapeutic strategy used in managing infective endocarditis caused by streptococcal species—most commonly viridans group streptococci, *Streptococcus gallolyticus*, or nutritionally variant streptococci The clinical concept of synergy applies when an aminoglycoside is combined with a cell-wall-active agent (such as a penicillin, ceftriaxone, or vancomycin) to achieve enhanced, rapid bactericidal activity, which facilitates shortene...

Synergy for streptococcal endocarditis refers to the adjunctive therapeutic strategy used in managing infective endocarditis caused by streptococcal species—most commonly viridans group streptococci, *Streptococcus gallolyticus*, or nutritionally variant streptococci

Affecting the cardiovascular system, primarily the native or prosthetic heart valves and the mural endocardium, this condition is characterized by bacteremia-induced endothelial damage leading to friable, infected platelet-fibrin vegetations

Affecting the cardiovascular system, primarily the native or prosthetic heart valves and the mural endocardium, this condition is characterized by bacteremia-induced endothelial damage leading to friable, infected platelet-fibrin vegetations

The clinical concept of synergy applies when an aminoglycoside is combined with a cell-wall-active agent (such as a penicillin, ceftriaxone, or vancomycin) to achieve enhanced, rapid bactericidal activity, which facilitates shortened therapy courses in uncomplicated native valve disease or provides necessary bacterial clearance against strains with reduced beta-lactam susceptibility